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Shanghai, Beijing, ChinaBackground and Aims: We aimed to investigate outcomes of pancreatic extracorporeal shock wave lithotripsy
(P-ESWL) for the removal of large pancreatic stones coexisting with pancreatic pseudocysts (PPCs) in chronic
pancreatitis (CP).
Methods: This is a prospective study performed in CP patients with at least 1 stone (5 mm). Patients were
divided into the PPC group (stones coexisting with PPCs) or the control group (stones alone). Patients were
initially subjected to successive P-ESWL treatments, followed by ERCP. Primary outcomes were P-ESWL adverse
events, and secondary outcomes were stone clearance, long-term pain relief, improved quality-of-life scores,
and PPC regression.
Results: A total of 849 patients (59 in the PPC group and 790 in the control group) was subjected to P-ESWL
between March 2011 and October 2013. Occurrences of P-ESWL adverse events were similar between the
PPC group and the control group (11.86% vs 12.41%, P Z .940). After the treatment of initial P-ESWL com-
bined with ERCP, the complete, partial, and nonclearance of stones occurred in 67.24%, 20.69%, and
12.07%, respectively, of patients in PPC group, with no signiﬁcant difference from the control group (com-
plete, partial, and nonclearance: 83.17%, 10.40%, and 11.39%, respectively; P Z .106). Fifty-ﬁve of 59 patients
(93.22%) with PPCs were followed for a median period of 21.9 months (range, 12.0-45.1). PPCs disappeared in
56.36% (31/55) and 76.36% (42/55) of patients after 3 months and 1 year of follow-up visits, respectively.
Moreover, complete and partial pain relief were achieved in 63.64% (35/55) and 25.45% (14/55) of patients,
respectively. The scores for quality of life (P < .001), physical health (P < .001), and weight loss (P < .001)
improved.
Conclusions: In our multispecialty tertiary center, initial P-ESWL followed by ERCP was safe in patients with co-
existing pancreatic stones and PPCs and effective for stone clearance, main pancreatic duct drainage, and pain
relief. (Gastrointest Endosc 2016;84:69-78.)ns: CP, chronic pancreatitis; SF-36, 36-Item Short-Form; MPD,
eatic duct; P-ESWL, pancreatic extracorporeal shock wave
PC, pancreatic pseudocyst.
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P-ESWL for stones coexisting with PPC Li et alApproximately 50% of patients with chronic pancreatitis
(CP) have developed pancreatic stones,1 and about 20% to
40% of patients with CP have developed pancreatic
pseudocysts (PPCs)2 during the course of disease. The
coexistence of PPCs and large stones, a condition mainly
associated with increased pressure in the pancreatic duct
caused by stones and/or stricture, is commonly observed.
This complicated condition is possibly closely related to
chronic pain and recurrent attacks of acute abdominal
pain and poses clinical challenges, especially because
treatment options have not been included in any
guideline and consensus on CP.3-7
Drainage of the main pancreatic duct (MPD) with
ERCP alone is often unsuccessful; thus, pancreatic extra-
corporeal shock wave lithotripsy (P-ESWL), an effective
and safe microinvasive method used to fragment large
pancreatic stones before ERCP, is needed to facilitate stone
clearance and improve the success rate of MPD drainage
via ERCP.2,8-11 However, the safety of initial P-ESWL
followed by ERCP in patients with PPCs remains to be
conﬁrmed considering the risks of adverse events directly
or indirectly related to PPC.
A multistep strategy that involves EUS-guided PPC
drainage and stent implantation/removal is usually needed
before P-ESWL and ERCP to drain PPCs and remove stones.
However, this multistep strategy renders high cumulative
risks and low success rates.6,12-14 Surgery is occasionally
performed as the primary choice or as a complementary
method, although these procedures are highly inva-
sive.4,15-17 Initial P-ESWL combined with ERCP, a simpliﬁed
microinvasive method that requires a short duration of
hospitalization, is a potential strategy. However, the safety
and efﬁcacy of this approach is yet to be conﬁrmed.
Only a few studies on P-ESWL involve patients with PPC;
thus, insufﬁcient information is available about the possi-
bility of PPC-related adverse events,9,18 such as pseudo-
aneurysm,19 rupture, and bleeding. The few studies that
include PPC cases presented no speciﬁc safety evaluation
of these patients.19-21 In addition, P-ESWL in patients
with PPCs has not been indicated in any guideline and
consensus on CP.3-7 Theoretically, P-ESWL should be safely
used for stone pulverization in patients with PPCs because
shock wave transmission through a PPC consumes a low
amount of energy. This article presents the results of initial
P-ESWL followed by ERCP in CP patients with coexisting
large pancreatic stones and PPCs to evaluate the safety
and effectiveness of this strategy in such patients.METHODS
This research was conducted to evaluate the prospec-
tive outcome of P-ESWL in patients with PPCs within the
speciﬁed period. Written informed consent was obtained
from each patient, and this study was approved by the
Ethics Committee of Changhai Hospital.70 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 1 : 2016Patients
CP was diagnosed mainly through CT, magnetic reso-
nance imaging (MRI), or EUS in accordance with the
Asia-Paciﬁc consensus.3 P-ESWL was recommended in
patients with painful CP and at least 1 pancreatic stone
with a diameter  5 mm. Patients suspected with or
diagnosed with malignancy, pancreatic ascites, and
pregnancy were disqualiﬁed for P-ESWL. Consecutive CP
patients who were subjected to P-ESWL from March 2011
to October 2013 were included. A PPC is a collection of
ﬂuid in the pancreatic or peripancreatic area with a well-
deﬁned wall containing no visible solid debris or recogniz-
able parenchymal necrosis.2 All patients included in this
study were routinely evaluated by contrast-enhanced CT
scan before P-ESWL; in addition, 3-dimensional imaging
stone reconstruction and curved planar reformatted imag-
ing of the MPD were conducted22 (Fig. 1).Treatment strategy
In this study patients were initially treated with P-ESWL
followed by ERCP. P-ESWL was performed by 2 gastroen-
terologists (L.H.H. and B.Y.) using an electromagnetic lith-
otripter (Compact Delta II; Dornier Medical Technology,
Wessling, Germany) with a bidimensional ﬂuoroscopic
targeting facility. In each patient a P-ESWL session was
repeated on consecutive days until the stones were frag-
mented down to a diameter  3 mm. Intravenous sedation
(a combination of ﬂurbiprofen and remifentanil) was
administered to induce analgesia during the procedure.
Meanwhile, shock waves per session were limited to a
maximum of 5000 shocks. During the procedure an inten-
sity ranging from 1 to 6 was used with a frequency of 60
to 120 shocks per minutes. Each session lasted for 60 to
90 minutes. After the last P-ESWL session was completed,
ERCP was performed to remove stone fragments and to
treat pancreatic duct stenosis. Pancreatic stents (5F-10F)
were inserted into patients with dominant MPD strictures
and/or pseudocysts that required a stent for drainage.2
The inserted stent was removed or replaced with a larger
stent after a year.2
For patients with PPC, a pancreatic surgery team stood
by while the study was ongoing. Transcutaneous drainage
was performed before P-ESWL in patients with palpable
masses of PPCs. In addition, shock wave intensity was ﬁxed
at level 6, and post-ESWL ERCP was performed 48 hours af-
ter the last P-ESWL session was completed.Baseline data collection
The demographic data and disease course of CP,
including onset, manifestations, diagnosis, previous treat-
ments, and assessment of quality of life, were recorded
in detail. A brief assessment of quality of life was based
on a scale of 1 to 10, wherein 1 represents the lowest qual-
ity of life and 10 represents the best quality of life.8
Additionally, quality-of-life scale scores, as a more objectivewww.giejournal.org
Figure 1. Curved planar reformatted imaging of MPD before and after treatment. A, A communicating PPC is located near a stone that obstructed the
clearly dilated MPD. B, A stent was in place 3 months after P-ESWL treatment, and no PPC was detectable. P-ESWL, pancreatic extracorporeal shock wave
lithotripsy; PPC, pancreatic pseudocyst; CP, chronic pancreatitis; MPD, main pancreatic duct.
Figure 2. Three types of PPC secondary to calciﬁed CP. Type I, PPC is directly associated to large stones: a communicating PPC is located near the stones
that obstruct the MPD and communication passage thereby directly causing PPC formation. Type II, PPC indirectly associated to large stones: a commu-
nicating PPC is at a considerable distance from the stones that obstruct the MPD, thereby indirectly causing PPC formation. Type III, PPC is seemingly not
associated to large stones: a noncommunicating PPC coexists with MPD obstructed by stones (some tiny communicating passages that are undetectable
by ERCP may exist). (Illustrated by J.-J.T.) PPC, pancreatic pseudocyst; CP, chronic pancreatitis; MPD, main pancreatic duct.
Li et al P-ESWL for stones coexisting with PPCassessment of quality of life, were also obtained using the
Medical Outcomes Study 36-Item Short-Form General
Health Survey (SF-36) questionnaire.23,24 Physical and
mental health was assessed from the SF-36 scores. PPC
characteristics (location, size, number, and communication
with the MPD) were based from CT and ERCP ﬁndings.
PPC classiﬁcation systems, such as D’Egidio and Schein, At-
lanta, and Nealon and Walser classiﬁcations, do not
consider the relationship between the occurrence of
stones and PPC formation.25-27
In this study PPCs in patients with calciﬁed CP were
classiﬁed into 3 types on the basis of the spatial relation-
ships among the stones, PPC, and pancreatic duct as
revealed by curved planar reformatted images of MPD
and ERCP ﬁndings (Fig. 2). For type I, PPCs are directly
associated with large stones, in which a communicating
PPC is located close to stones that obstruct the MPD and
communication passage, which directly result in PPC
formation. For type II, PPCs are indirectly related to large
stones, wherein a communicating PPC is located at a
considerable distance from the stones that obstruct
the MPD, thereby indirectly causing PPC formation. For
type III, PPCs are seemingly unrelated to large stones,www.giejournal.orgwherein a noncommunicating PPC coexists with the MPD
obstructed by stones (some tiny communicating passages
that are undetectable by ERCP possibly exist).
Outcome measures
Patients were carefully evaluated after each P-ESWL
session and post-ESWL ERCP. Adverse events observed
during the 1-month period after P-ESWL and relevant
treatments were documented. Patients with PPCs were
required for revisit after 3 months, 6 months, 1 year, and
every other year. Noncontrast CT scan of the pancreas
was performed at each follow-up visit until the PPCs disap-
peared. In addition, 3-dimensional imaging stone recon-
struction and curved planar reformatted imaging of the
MPD were conducted for evaluation. An evaluation modal-
ity (US, MRI, or CT scan) was performed at each follow-up
visit after PPCs disappeared. In November 2014 all PPC
patients included in this study except those lost dur-
ing the follow-up period were evaluated. Moreover, a
second round of assessment using the SF-36 questionnaire
was conducted. The primary outcomes were P-ESWL
adverse events, including post-ESWL pancreatitis, infec-
tion, bleeding, perforation, and steinstrasse (Table 1).28,29Volume 84, No. 1 : 2016 GASTROINTESTINAL ENDOSCOPY 71
TABLE 1. Definitions of major adverse events of pancreatic extracorporeal shock wave lithotripsy28
Adverse events* Mild Moderate Severe
Post-ESWL pancreatitis Clinical pancreatitis, amylase at least
3 times the normal level at >24 h after
procedure, requires admission or extension
of planned admission from 2 to 3 days
Requires hospitalization
for 4-10 days
Hospitalization for >10 days,
pseudocyst, or intervention
(percutaneous drainage or surgery)
Bleedingy Clinical evidence of bleeding,
hemoglobin drop < 3 g,
no transfusion
Transfusion (4 units),
no angiographic
intervention, or surgery
Transfusion  5 units or intervention
(angiographic or surgical)
Infection >38C for 24-48 h Requires hospitalization
for >3 days
Abscess, septic shock, or intervention
(percutaneous drainage or surgery)
Steinstrassez Severe abdominal pain without
other post-ESWL adverse events
Combined with other adverse
events, or requires >3 days of
hospital treatment
Combined with other adverse events;
hospitalization for >10 days, or surgery
Perforation Possible, or very slight leak
of fluid, treatable with fluids and
suction for 3 days
Any definite perforation treated
medically for 4-10 days
Medical treatment for >10 days or
intervention (percutaneous or surgical)
ESWL, extracorporeal shock wave lithotripsy.
*Splenic rupture, pancreaticobiliary fistula, and other rare adverse events are not included in this classification of adverse events.28
yAcute GImucosal injury is not included but is classified as a transient adverse event.
zSteinstrasse29: Acute stone incarceration in the papilla, leading to poor pancreatic juice drainage. CT shows a more dilated pancreatic duct with/without acute pancreatitis.
Severe abdominal pain that cannot be relieved by analgesics can be relieved by emergency ERCP or ESWL.
P-ESWL for stones coexisting with PPC Li et alSecondary outcomes were stone clearance and long-term
clinical outcomes, such as pain relief, weight gain,
quality-of-life scores, and outcome of pseudocysts (regres-
sion, disappearance or evident decrease in size; no regres-
sion, stabilization or increase in size) during the follow-up
period. Pain relief was graded on the basis of the following
3-point Likert scale: complete relief, no pain occurred dur-
ing the follow-up period; partial relief, decreased episodes
and intensity of pain; and no relief, no change in the symp-
tom of pain.
Statistical analysis
Continuous variables are presented as mean (SD) or me-
dian (range), whereas categorical variables are presented as
numbers with proportions. The t test and c2 test (or the
Fisher exact test as indicated) were used to analyze the dif-
ference of patients’ characteristics and adverse event rates
between the PPC group and the control group. The Wil-
coxon rank test was used to compare pre-ESWL and last
contact quality-of-life scores and weights for the PPC group.
Statistical signiﬁcance was considered at P < .05.RESULTS
A total of 849 CP patients were subjected to P-ESWL
between March 2011 and October 2013. Of the 849 CP
patients, 59 manifested PPCs (PPC group) and 790 had
no PPCs (control group) (Table 2). Compared with the
control group, the PPC group included more male
patients (86.44% vs 69.87%, P Z .007), fewer patients
with diabetes mellitus (13.56% vs 28.99%, P Z .011), and
more patients with alcoholic CP (45.76% vs 24.18%,
P Z .001).72 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 1 : 2016In the PPC group, 74.58% of patients (44/59) manifested
PPCs with a diameter < 4.0 cm, and 10.17% of patients
(6/59) exhibited PPCs with a diameter of 4.0 to 6.0 cm.
Notably, the largest PPC measured 10.0 cm  8.0 cm
(Table 3). Meanwhile, 28.81% of patients (17/59)
experienced intensifying pain in the last 3 months
as per results of the independent evaluation by 2
gastroenterologists who based their ﬁndings on recent
changes in the frequency and severity of pain (any
disagreement was resolved by discussion between the 2
gastroenterologists). Moreover, 14 patients in the PPC
group were treated with ERCP before P-ESWL at a local
hospital in an attempt to drain the MPD; however, the
procedures were unsuccessful. Two patients with
palpable PPCs (10.0 cm  7.0 cm and 10.0 cm  8.0 cm)
underwent transcutaneous drainage before P-ESWL, and
the PPCs were successfully drained (PPCs measured
2.0 cm  2.0 cm and 4.5 cm  3.5 cm when P-ESWL was
performed; drain tubes were removed 3 days after ERCP
was performed).
Overall, 59 patients in PPC group were subjected to 116
P-ESWL sessions. The targeted stones in all patients were
successfully fragmented within an average of 2 P-ESWL
sessions, with mean  SD shock waves of 9920.34 
5436.84. After P-ESWL was performed, complete and
partial spontaneous stone clearance occurred in 10.17%
(6/59) and 15.25% (9/59) of patients, respectively; 44.07%
(26/59), 5.08% (3/59), and 50.85% (30/59) accounted
for type I, II, and III PPCs, respectively. ERCP ﬁndings
showed 67.8% of patients (40/59) exhibited dominant
MPD stricture (Table 4). After the treatment of initial
P-ESWL combining with ERCP, the complete, partial, and
nonclearance of stones occurred in 67.24% (39/58),
20.69% (12/58), and 12.07% (7/58) of patients, with nowww.giejournal.org
TABLE 2. General characteristics of patients with P-ESWL with/without PPCs
ESWL with PPC (n [ 59) ESWL without PPC (n [ 790) P value
Age at CP onset 36.2  13.8 34.8  15.1 .486
Age at CP diagnosis 41.5  13.3 40.8  14.3 .683
Age [stone(s)] 41.6  13.3 41.0  14.2 .773
Male 51 86.44% 552 69.87% .007
Adolescent 7 11.86% 123 15.57% .446
Etiology .001
ACP 27 45.76% 191 24.18%
ICP 31 52.54% 545 68.99%
Others 1 1.69% 54 6.84%
Symptom at CP onset .004
Abdominal pain 56 94.92% 612 77.47%
DM/steatorrhea 2 3.39% 130 16.46%
Others 1 1.69% 48 6.08%
Type of abdominal pain .001
RAP 17 28.81% 260 32.91%
RP 11 18.64% 263 33.29%
RAP/P 30 50.85% 211 26.71%
CPP 1 1.69% 56 7.09%
DM 8 13.56% 229 28.99% .011
Steatorrhea 11 18.64% 183 23.16% .425
SAP 3 5.08 20 2.53% .211
CBD stenosis 5 8.47% 73 9.24% .844
Values are mean  SD or number of cases and percents.
CP, chronic pancreatitis; SF-36, 36-Item Short-Form; MPD, main pancreatic duct; P-ESWL, pancreatic extracorporeal shock wave lithotripsy; PPC, pancreatic pseudocyst; ACP,
Alcoholic chronic pancreatitis; ICP, idiopathic chronic pancreatitis; DM, diabetes mellitus; RAP, recurrent acute pancreatitis; RAP/P, recurrent acute pancreatitis or abdominal pain
without significant increase in serum amylase; CPP, chronic pancreatic pain; SAP, severe acute pancreatitis; CBD, common bile duct.
Li et al P-ESWL for stones coexisting with PPCsigniﬁcant difference from the control group (complete,
partial, and nonclearance: 83.17%, 10.40%, and 11.39%,
respectively; P Z .106). MPD drainage was successful in
56 of 59 patients (94.92%), which was also similar to the
result obtained in the control group (89.49%, P Z .183).
There was no signiﬁcant difference in the number of
adverse events of P-ESWL (11.86% vs 12.41%, P Z .940)
between the PPC and control groups or in rates of speciﬁc
adverse events of P-ESWL (Table 5). Both groups had a
similar median number of ESWL sessions (2 [range, 1-5]
vs 2 [range, 1-12], respectively; P Z .288). In the PPC
group, P-ESWL adverse events were observed in 7 of 59
patients (11.86%) (including 7 of 116 P-ESWL sessions
[6.03%]); among these patients, 4 showed mild post-
ESWL pancreatitis, 2 manifested infection, and 1 exhibited
an enlarged PPC accompanied by severe abdominal pain.
In the control group, adverse events were observed in 98
of 790 patients (12.41%); among these patients, 71 ex-
hibited post-ESWL pancreatitis (8.99%), 15 had infection
(1.90%), 4 experienced bleeding (.51%), 4 manifested
perforation (.51%), 6 showed steinstrasse (.76%), and 1 dis-
played pancreatic ﬁstula (.13%). In the PPC group, the pa-
tient with an enlarged PPC after P-ESWL was transferred towww.giejournal.orgour surgical department for stone extraction and PPC
drainage. CT revealed no signs of acute pancreatitis in
this patient. As observed during the operation, the
enlarged PPC was caused by the piling of stone fragments.
This phenomenon resulted in the complete obstruction of
the passage involved in the communication between the
PPCs and the pancreatic duct. In the control group, no pa-
tient with P-ESWL adverse events was treated via surgery.
Rates of ESWL-related adverse events were 7.69%, 0.00%,
and 16.67%, respectively, for the 3 PPC types. Transient
adverse events28 that required no medical intervention
and did not prolong hospitalization occurred in 30.51%
(18/59) of patients or 21.55% (25/116) of P-ESWL sessions;
these events include asymptomatic hyperamylasemia
(14/18), hematuria (3/18), and acute GI injury (1/18). Skin
erythema and mild tenderness of the shock wave head-
contacting region were observed in almost all patients.
Among the 59 patients, the patient transferred to sur-
gery was not involved in the analysis of PPC regression
and 3 patients were lost to follow-up. The remaining 55
patients were observed within a median duration of 21.9
months (range, 12-45.1). PPCs disappeared in 56.36% (31/
55) and 76.36% (42/55) of patients after 3 months and 1Volume 84, No. 1 : 2016 GASTROINTESTINAL ENDOSCOPY 73
TABLE 3. Characteristics of PPC and stones in included patients
n %
Age of P-ESWL with PPC 42.98  12.89*
Interval between CP onset and P-ESWL 6.77  6.28*
Size of PPC (diameter)
<1 cm 2 3.39
1-4 cm 42 71.19
4-6 cm 9 15.25
6 cm 6 10.17
No. of PPC
1 48 81.36
2 5 8.47
3-5 6 10.17
Location of PPC
Head 32 54.24
Body 7 11.86
Head and body 1 1.69
Tail 19 32.20
Intensifying pain recentlyy 17 28.81
No. of stone(s)z
1-3 5 8.47
4-20 12 20.34
>20 42 71.19
Location of stone(s)
Head 14 23.73
Tail 2 3.39
Head and at least another location 43 72.88
Size of stones (diameter)
.5-1 cm 22 37.29
1-2 cm 29 49.15
2-3 cm 6 10.17
3 cm 2 3.39
CP, chronic pancreatitis; P-ESWL, pancreatic extracorporeal shock wave lithotripsy;
PPC, pancreatic pseudocyst.
*Mean  SD.
yIntensifying pain was characterized by more severe, more frequent, or more lasting
pain attacks during the last 3 months.
zNumber of stones was calculated by built-in software (Somaris/5 syno CT 2007S,
syno CT workplace VB30B) in Siemens Sensation Cardiac 64 CT (SOMATOM, Siemens,
Munich, Germany). Stones no less than 1 mm in diameter can be identified as an
individual stone.
TABLE 4. Findings and procedural characteristics in post-ESWL ERCP
n %
Type of PPC*
Type I 26 44.07
Type II 3 5.08
Type III 30 50.85
MPD stricture* 40 67.80
MPD diameter 56
<.8 cm 27 48.21
.8 cm, <1.0 cm 9 16.07
1.0 cm, <1.5 cm 14 25.00
1.5 cm 6 10.71
ERCP procedurey
Stone extractionz 27 45.76
EPT 37 62.71
Bougie dilation 18 30.51
Balloon dilation 9 15.25
Pancreatic stent 41 69.49
Successful drainagey 56 94.92
Clearance of stonesx 58
Complete (>90%) 39 67.24
Partial (50%-90%) 12 20.69
None (<50%) 7 12.07
EPT, Endoscopic papillotomy; CP, chronic pancreatitis; MPD, main pancreatic duct;
ESWL, extracorporeal shock wave lithotripsy; PPC, pancreatic pseudocyst.
*Two patients with failed ERCP were evaluated by MRCP and EUS before P-ESWL was
performed.
yOne patient underwent surgery without post-ESWL ERCP, 2 patients received
unsuccessful ERCP, and the 56 remaining patients had successful MPD drainage via
post-ESWL ERCP.
zSpontaneous clearance of stone fragments after P-ESWL(s) alone occurred in some
patients, and thus no stone extraction procedure was needed during ERCP; in some
patients, stone extraction during ERCP was impractical or unsuccessful.
xThe degree of MPD clearance is defined as follows9: complete clearance, clearance
> 90% of stone volume; partial clearance, clearance of 50%-90% of stone volume;
and unsuccessful clearance, clearance < 50% of stone volume.
P-ESWL for stones coexisting with PPC Li et alyear of follow-up visits, respectively (Table 6). The
resolution rates of PPCs for the 3 types were 95.83%
(23/24), 100.00% (3/3), and 57.14% (16/28) in 1 year. A
signiﬁcantly higher resolution rate was detected in the
patients with type I PPC than in those with type III PPC
(P Z .001). Three of the 13 patients who had persistent
PPC showed a decrease in PPC size within a year of follow-
up. Since then, no change in PPC regression was observed
until the last follow-up session. In addition, no PPC recur-
rence was observed during the follow-up period (Fig. 3).74 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 1 : 2016Up until the last contact, complete pain relief and
partial palliation were achieved in 63.64% (35/55) and
25.45% (14/55) of patients, respectively. Median scores
for quality of life (6.5 [range, 4.0-1.0] vs 8.5 [range, 5.0-
1.0], P < .001) and physical health from the SF-36 (95
[range, 35-100] vs 100 [range, 75 -100], P < .001) improved
after ESWL. No difference was observed in the mental
health scores (Table 7). Signiﬁcant weight gain was
observed at the last contact compared with that in pre-
ESWL (P < .001).DISCUSSION
We present an initial report on the results of P-ESWL
performed to a large number of patients with calciﬁed
CP and PPCs. The presence of PPCs did not increase the
risk of ESWL-related adverse events. Also, P-ESWLwww.giejournal.org
TABLE 5. Complications of P-ESWL with/without PPC
Adverse events
P-ESWL with PPCs (n [ 59) P-ESWL without PPCs (n [ 790)
P valuen % n %
Type
Post-ESWL pancreatitis 4 6.78 71 8.99 .564
Infection 2 3.39 15 1.90 .333
Bleeding 0 .00 4 .51 1.000
Perforation 0 .00 4 .51 1.000
Steinstrasse 0 .00 6 .76 1.000
Others 1* 1.69 1y 0.13 .134
Severity
Mild 6 10.17 79 10.00 .967
Moderate to severe 1 1.69 19 2.41 .729
Total adverse events 7 11.86 98z 12.41 .940
P-ESWL, pancreatic extracorporeal shock wave lithotripsy; PPC, pancreatic pseudocyst.
*With enlarged PPCs, this patient was transferred to surgical therapy.
yOne patient had a pancreatic fistula.
zAdverse events were observed in 98 patients involved in 101 ESWL procedures.
TABLE 6. Regression of PPC during 1-year follow-up
Type With follow-up Without follow-up
PPC disappearance
After 3 months P value After 1 year P value
I 24 2* 19 (79.17%) 23 (95.83%)
II 3 0 3 (100.00%) 3 (100.00%)
III 28 2 9 (32.14%) 16 (57.14%)
Overall 55 4 31 (56.36%) <.001y 42 (76.36%) .001y
PPC, pancreatic pseudocyst.
*One patient underwent surgery.
yThe rates of PPC disappearance were compared between type I group and type III group, and P values were calculated.
Li et al P-ESWL for stones coexisting with PPCcombined with post-ESWL ERCP is an effective strategy for
stone clearance and PPC regression.
The patients involved in this study have painful CP coex-
istingwith PPCs and large stones. They required P-ESWL that
breaks large stones to facilitate MPD drainage via ERCP.
However, whether or not P-ESWL can be safely performed
when PPCs coexist with CP remains unclear. This complex
condition can be managed by performing multistep inter-
ventional procedures, including prior interventions for
PPC drainage (transcutaneous, transmural, or transpapilla
method) followed by P-ESWLs and ERCP.6,12-14 Alternatively,
surgerymay be performed. Themultistep-intervention strat-
egy is characterized by a high risk and low success rate,
whereas surgical treatment is macroinvasive. In the current
study, initial P-ESWL followed by ERCP was performed as a
simpliﬁed strategy to accomplish both MPD and PPC
drainage. The results of short- and long-term follow-up
sessions showed that this strategy is safe, effective, and
promising.
The nature of shock waves indicates that P-ESWL is safe
for the fragmentation of pancreatic stones coexisting with
PPCs. In fact, a sink ﬁlled with water was used as thewww.giejournal.orgcoupling equipment in ESWL when ESWL was ﬁrst intro-
duced to clinical practice for lithotripsy. Today, a water
capsule replaces the water-ﬁlled sink as the coupling
equipment. Similarly, ﬂuid-ﬁlled PPCs may consume low
energy from the shock waves and may not rupture during
P-ESWL. In 1992 Delhaye et al20 observed the occurrence
of PPCs in 34% of patients (42/123) treated with P-ESWL.
Coexistence of PPCs and stones improved CP diagnosis
via relatively low-resolution imaging and immature endo-
scopic technologies in the 1990s, which might have
contributed to the higher rate of PPC/cyst in CP in that
research. The cyst regression rate became 74% (31/42)
shortly after P-ESWL combined with ERCP(S), and PPC
disappearance was observed mainly in small PPCs
(<5 cm) and in cysts on the head of the pancreas. How-
ever, the treatment course of these 42 patients was not
described; detailed information on PPCs (such as size and
location), results on adverse events of P-ESWL, and long-
term outcome of PPCs were not reported. Johanns et al21
observed the disappearance of PPCs 3 months after P-
ESWL in 2 cases of coexisting CP and PPC. Meanwhile,
Nakagawa et al19 detected hemorrhagic pseudoaneurysmVolume 84, No. 1 : 2016 GASTROINTESTINAL ENDOSCOPY 75
Figure 3. Initial ESWL followed by ERCP was successfully performed in a CP patient with coexisting large stones and PPCs: a typical case. A, Before treat-
ment, a communicating PPC was found close to the stones that obstructed the clearly dilated MPD (type I PPC based on classiﬁcation). B and C, Multiple
small stones in the branch duct and the stent in place are revealed by 3D imaging stone reconstruction 3 months after treatment; in addition, no PPC was
detected through curved planar reformatted imaging of MPD. D, At the last follow-up visit, the MPD showed no dilation, and no PPC recurrence was
detected (the stent had been removed a year after treatment). CP, chronic pancreatitis; MPD, main pancreatic duct; ESWL, extracorporeal shock wave
lithotripsy; PPC, pancreatic pseudocyst.
TABLE 7. Outcomes of P-ESWL treatment for patients in PPC group during follow-up*
Pre-ESWL Follow-up P value
Quality-of-life scores, median (range) 6.5 (4.0-1.0) 8.5 (5.0-1.0) <.001
SF-36 quality-of-life scores
Physical health, median (range) 95 (35-100) 100 (75-100) <.001
Mental health, median (range) 68 (36-100) 76 (28-100) .423
Weight (kg), median (range) 60.0 (40.0-85.5) 63.5 (40.0-98.0) <.001
Diabetes, n (%) 10 (18.18%) 11 (20.00%) .500
Steatorrhea, n (%) 9 (16.36%) 11 (20.00%) .500
P-ESWL, pancreatic extracorporeal shock wave lithotripsy; PPC, pancreatic pseudocyst.
*A total of 55 (93.22%) patients completed the evaluation up to the last follow-up.
P-ESWL for stones coexisting with PPC Li et alafter P-ESWL in a patient with PPCs. Overall, reports on P-
ESWL performed in cases with coexisting CP and PPC are
rare, and systemic evaluation of the safety and long-term ef-
ﬁcacy of the procedure is lacking.
PPC rupture and bleeding are the most severe antici-
pated adverse events of P-ESWL, but these adverse events76 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 1 : 2016were not observed in the present study. An adverse event
characterized by an enlarged PPC and severe abdominal
pain after a P-ESWL session occurred in 1 patient. This
patient was subjected to surgery, during which the
enlarged PPC was found to have caused by the piling of
stone fragments, resulting in the complete obstruction ofwww.giejournal.org
Li et al P-ESWL for stones coexisting with PPCthe passage involved in the communication between the
PPCs and the MPD. Additional P-ESWL sessions may
improve the release of the obstruction in the passage
involved in the communication between the PPCs and
the MPD; however, the risk of surgery is signiﬁcantly
increased if the additional P-ESWL sessions fail to achieve
obstruction release and triggered acute pancreatitis. There-
fore, surgery was chosen in this case after a multidisci-
plinary discussion was conducted. When the simpliﬁed
approach (P-ESWL followed by ERCP) is practiced in CP
with PPC, it is necessary that multispecialty professionals
are available around the clock, both for clinical decision-
making and dealing with undesired events.
Nakagawa et al19 reported a case of hemorrhagic
pseudoaneurysm after P-ESWL was performed; this
condition may be attributed to the inappropriate
selection of P-ESWL. Speciﬁc conditions in this patient
may have aggravated the high risk of P-ESWL adverse
events. An isolated stone was located in the pancreas tail;
a high-pressure PPC was found near the splenic hilum,
which is possibly a type III PPC in accordance with our
classiﬁcation scheme (unrelated to the isolated stone in
the pancreas tail), and pancreatic portal hypertension
was detected. For the isolated pancreatic tail stone with
type I PPC, P-ESWL is still a good choice to drain the
pancreatic duct and the PPCs. In our study, the MPD and
PPCs in 2 patients with type I PPCs were drained via frag-
mentation of the isolated stone in the pancreas tail
through P-ESWL. No adverse events occurred.
In the classiﬁcation proposed by D’Egidio and Schein,25
PPCs in CP included 2 types: postnecrotic PPCs (acute-on-
CP attack; diseased MPD morphology but without evident
stricture) and retention PPC (no acute attack, evident MPD
stricture, and PPCs communicating with the pancreatic
duct). The Atlanta classiﬁcation distinguishes acute PPCs
(associated with an attack of acute pancreatitis more than
4 weeks ago) and chronic PPCs (arising in patients with
CP and no antecedent acute pancreatitis).26 These
classiﬁcations are helpful in management decisions;
however, the effect of stone on PPC formation and
regression was not considered. Thus, we proposed a
classiﬁcation scheme for PPCs in CP cases on the basis of
the spatial relationship among the pancreatic duct,
stones, and PPCs. Types I and II PPCs, which are
supposedly communicating with the pancreatic duct,
mostly disappeared during the follow-up period. More
than half of the type III PPCs disappeared during the
follow-up period, possibly because there are tiny passages
communicating PPC with the MPD and decreased pressure
in the MPD facilitates PPC drainage. Overall, PPCs disap-
peared in 76% of the patients. However, the efﬁciency of
the initial P-ESWL combined with ERCP strategy on PPC
regression needs further conﬁrmation, because PPCs may
achieve spontaneous resolution without any interventions.
A number of limitations were encountered in this study.
First, a randomized control study is necessary to comparewww.giejournal.orgthe outcomes of the initial P-ESWL strategy, multistep-
intervention strategy, and surgery in patients with coexist-
ing calciﬁed CP and PPCs. Second, a longer follow-up
period should be allotted to further evaluate the improve-
ment of abdominal pain and PPC recurrence. Third, only 6
of 59 patients (10.17%) with large PPCs (6 cm in diam-
eter) received ESWL. Thus, a larger patient group is needed
to conﬁrm the safety of P-ESWL for calciﬁed CP with large
PPCs. However, the conclusion drawn from this study is
signiﬁcant in performing P-ESWL in CP patients with PPCs
because most PPCs secondary to CP patients are less
than 6 cm. Additionally, all subjects included were symp-
tomatic (abdominal pain) in this research, which indicates
interventions to remove MPD stones, drain the PPC, and
eventually achieve symptom relief.
We conclude that in a multispecialty tertiary center,
initial P-ESWL followed by ERCP is an effective and safe
treatment to clear large pancreatic stones coexisting with
PPCs, to drain MPD, and possibly to eliminate PPCs.
Overall, this study extensively explored the application of
P-ESWL.REFERENCES
1. Rosch T, Daniel S, Scholz M, et al. Endoscopic treatment of chronic
pancreatitis: a multicenter study of 1000 patients with long-term
follow-up. Endoscopy 2002;34:765-71.
2. Dumonceau JM, Delhaye M, Tringali A, et al. Endoscopic treatment of
chronic pancreatitis: European Society of Gastrointestinal Endoscopy
(ESGE) Clinical Guideline. Endoscopy 2012;44:784-96.
3. Tandon RK, Sato N, Garg PK. Chronic pancreatitis: Asia-Pacific
consensus report. J Gastroenterol Hepatol 2002;17:508-18.
4. Bornman PC, Botha JF, Ramos JM, et al. Guideline for the diagnosis and
treatment of chronic pancreatitis. S Afr Med J 2010;100:845-60.
5. Adler DG, Lichtenstein D, Baron TH, et al. The role of endoscopy in
patients with chronic pancreatitis. Gastrointest Endosc 2006;63:933-7.
6. Jacobson BC, Baron TH, Adler DG, et al. ASGE guideline: The role of
endoscopy in the diagnosis and the management of cystic lesions
and inflammatory fluid collections of the pancreas. Gastrointest
Endosc 2005;61:363-70.
7. Liao Z, Jin G, Cai D, et al. Guidelines: diagnosis and therapy for chronic
pancreatitis. J Interv Gastroenterol 2013;3:133.
8. Seven G, Schreiner MA, Ross AS, et al. Long-term outcomes associated
with pancreatic extracorporeal shock wave lithotripsy for chronic
calcific pancreatitis. Gastrointest Endosc 2012;75:997-1004.
9. Tandan M, Reddy DN, Santosh D, et al. Extracorporeal shock wave lith-
otripsy and endotherapy for pancreatic calculi-a large single center
experience. Indian J Gastroenterol 2010;29:143-8.
10. Dumonceau JM, Costamagna G, Tringali A, et al. Treatment for painful
calcified chronic pancreatitis: extracorporeal shock wave lithotripsy
versus endoscopic treatment: a randomised controlled trial. Gut
2007;56:545-52.
11. Hu LH, Du TT, Liao Z, et al. Extracorporeal shock wave lithotripsy as a
rescue for a trapped stone basket in the pancreatic duct. Endoscopy
2014;46:E332-3.
12. Antillon MR, Shah RJ, Stiegmann G, et al. Single-step EUS-guided trans-
mural drainage of simple and complicated pancreatic pseudocysts.
Gastrointest Endosc 2006;63:797-803.
13. Kahaleh M, Shami VM, Conaway MR, et al. Endoscopic ultrasound
drainage of pancreatic pseudocyst: a prospective comparison with
conventional endoscopic drainage. Endoscopy 2006;38:355-9.Volume 84, No. 1 : 2016 GASTROINTESTINAL ENDOSCOPY 77
P-ESWL for stones coexisting with PPC Li et al14. Park DH, Lee SS, Moon SH, et al. Endoscopic ultrasound-guided versus
conventional transmural drainage for pancreatic pseudocysts: a pro-
spective randomized trial. Endoscopy 2009;41:842-8.
15. Kohler H, Schafmayer A, Ludtke FE, et al. Surgical treatment of pancre-
atic pseudocysts. Br J Surg 1987;74:813-5.
16. Rosso E, Alexakis N, Ghaneh P, et al. Pancreatic pseudocyst in chronic
pancreatitis: endoscopic and surgical treatment. Dig Surg 2003;20:
397-406.
17. Varadarajulu S, Lopes TL, Wilcox CM, et al. EUS versus surgical cyst-
gastrostomy for management of pancreatic pseudocysts. Gastrointest
Endosc 2008;68:649-55.
18. Bhasin DK, Rana SS. Extracorporeal shock wave lithotripsy (ESWL) for
large pancreatic stones: are these shocks worthwhile? Indian J Gastro-
enterol 2010;29:133-6.
19. Nakagawa Y, Abe T, Uchida M, et al. Hemorrhagic pseudoaneurysm in
a pancreatic pseudocyst after extracorporeal shock wave lithotripsy for
pancreatolithiasis. Endoscopy 2011;43(Suppl 2 UCTN):E310-1.
20. Delhaye M, Vandermeeren A, Baize M, et al. Extracorporeal shock-wave
lithotripsy of pancreatic calculi. Gastroenterology 1992;102:610-20.
21. Johanns W, Jakobeit C, Greiner L, et al. Ultrasound-guided extracorpo-
real shock wave lithotripsy of pancreatic ductal stones: six years’ expe-
rience. Can J Gastroenterol 1996;10:471-5.GIE on LinkedIn
Follow GIE on LinkedIn. Followers will rece
interviews, podcasts, articles, and tables of 
Gastrointestinal Endoscopy with Editor Mic
78 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 1 : 201622. Ye B, Du TT, Hu LH, et al. Hilar hematoma after extracorporeal shock
wave lithotripsy for pancreatic stones. J Interv Gastroenterol 2013;3:
141-2.
23. Cahen DL, Gouma DJ, Laramee P, et al. Long-term outcomes of endo-
scopic vs surgical drainage of the pancreatic duct in patients with
chronic pancreatitis. Gastroenterology 2011;141:1690-5.
24. Cahen DL, Gouma DJ, Nio Y, et al. Endoscopic versus surgical drainage
of the pancreatic duct in chronic pancreatitis. N Engl J Med 2007;356:
676-84.
25. D'Egidio A, Schein M. Pancreatic pseudocysts: a proposed classification
and its management implications. Br J Surg 1991;78:981-4.
26. Bradley EL, 3rd. A clinically based classification system for acute pancre-
atitis. Summary of the International Symposium on Acute Pancreatitis,
Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993;128:586-90.
27. Nealon WH, Walser E. Main pancreatic ductal anatomy can direct
choice of modality for treating pancreatic pseudocysts (surgery versus
percutaneous drainage). Ann Surg 2002;235:751-8.
28. Li BR, Liao Z, Du TT, et al. Risk factors for complications of pancreatic
extracorporeal shock wave lithotripsy. Endoscopy 2014;46:1092-100.
29. Hu LH, Liu MH, Liao Z, et al. Steinstrasse formation after extracorporeal
shock wave lithotripsy for pancreatic stones. Am J Gastroenterol
2012;107:1762-4.ive news, updates, and links to author
contents. Search on LinkedIn for “GIE: 
hael B. Wallace” and follow us today.  
www.giejournal.org
